Tags

Type your tag names separated by a space and hit enter

Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
Int J Tuberc Lung Dis 1998; 2(10):824-30IJ

Abstract

SETTING

The absorption of rifampicin, isoniazid and pyrazinamide was tested after administration of each drug in free combinations and in a fixed-dose combination of the three drugs, known as Trifazid.

OBJECTIVE

To examine the relative bioavailability of rifampicin, isoniazid and pyrazinamide after oral administration of the drugs given alone in comparison to that of the same drugs after administration of Trifazid.

DESIGN

An open, randomized, cross-over study comprising 16 healthy volunteers.

RESULTS

The pattern of absorption, plasma concentrations and pharmacokinetic parameters were very similar after administration of the drugs in free and fixed combinations.

CONCLUSION

The triple combination of antituberculosis drugs could replace the separate drugs in the treatment of tuberculosis.

Authors+Show Affiliations

National Research Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9783530

Citation

Zwolska, Z, et al. "Bioavailability of Rifampicin, Isoniazid and Pyrazinamide From Fixed-dose Combination Capsules." The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, vol. 2, no. 10, 1998, pp. 824-30.
Zwolska Z, Niemirowska-Mikulska H, Augustynowicz-Kopec E, et al. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules. Int J Tuberc Lung Dis. 1998;2(10):824-30.
Zwolska, Z., Niemirowska-Mikulska, H., Augustynowicz-Kopec, E., Walkiewicz, R., Stambrowska, H., Safianowska, A., & Grubek-Jaworska, H. (1998). Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules. The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, 2(10), pp. 824-30.
Zwolska Z, et al. Bioavailability of Rifampicin, Isoniazid and Pyrazinamide From Fixed-dose Combination Capsules. Int J Tuberc Lung Dis. 1998;2(10):824-30. PubMed PMID: 9783530.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules. AU - Zwolska,Z, AU - Niemirowska-Mikulska,H, AU - Augustynowicz-Kopec,E, AU - Walkiewicz,R, AU - Stambrowska,H, AU - Safianowska,A, AU - Grubek-Jaworska,H, PY - 1998/10/23/pubmed PY - 1998/10/23/medline PY - 1998/10/23/entrez SP - 824 EP - 30 JF - The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease JO - Int. J. Tuberc. Lung Dis. VL - 2 IS - 10 N2 - SETTING: The absorption of rifampicin, isoniazid and pyrazinamide was tested after administration of each drug in free combinations and in a fixed-dose combination of the three drugs, known as Trifazid. OBJECTIVE: To examine the relative bioavailability of rifampicin, isoniazid and pyrazinamide after oral administration of the drugs given alone in comparison to that of the same drugs after administration of Trifazid. DESIGN: An open, randomized, cross-over study comprising 16 healthy volunteers. RESULTS: The pattern of absorption, plasma concentrations and pharmacokinetic parameters were very similar after administration of the drugs in free and fixed combinations. CONCLUSION: The triple combination of antituberculosis drugs could replace the separate drugs in the treatment of tuberculosis. SN - 1027-3719 UR - https://www.unboundmedicine.com/medline/citation/9783530/Bioavailability_of_rifampicin_isoniazid_and_pyrazinamide_from_fixed_dose_combination_capsules_ L2 - https://www.ingentaconnect.com/openurl?genre=article&issn=1027-3719&volume=2&issue=10&spage=824&aulast=Zwolska DB - PRIME DP - Unbound Medicine ER -